No Detail Found!

Clinicopathological Features of Gastroenteropancreatic Neuroendocrine Neoplasms

Author(s)
Abdusselam Sekerci Department of Internal Medicine, Faculty of Medicine, Bezmialem Vakif University, Turkey
Haci Mehmet Turk Department of Medical Oncology, Faculty of Medicine, Bezmialem Vakif University, Turkey
Tarik Demir Department of Medical Oncology, Faculty of Medicine, Bezmialem Vakif University, Turkey
Mesut Seker Department of Pathology, Faculty of Medicine, Bezmialem Vakif University, Turkey
Adem Akcakaya Department of General Surgery, Faculty of Medicine, Bezmialem Vakif University, Turkey
Dilek Sema Arici Department of Pathology, Faculty of Medicine, Bezmialem Vakif University, Turkey
Abstract
Objective: To describe the clinical, pathological and survival characteristics of Turkish patients with gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Study Design: Descriptive study. Place and Duration of Study: Bezmialem Vakif University School of Medicine Hospital from April 2012 to September 2018. Methodology: Sixty-one patients with GEP-NENs were analysed in retrospect for the clinical, pathological and survival characteristics. The Kaplan-Meier method was used for survival analysis and the Log-rank test was performed to analyse the comparisons between the groups. Results: Forty- ve of the 61 GEP-NENs patients (73.8%) were neuroendocrine tumor (NET) and 26.2% of patients were neuroendocrine carcinoma (NEC). The mean age of patients was 55.5 ± 11.3 years. The most frequent localisation of tumors was stomach (34.4%), and the most common symptom was abdominal pain (27.9%). The rate of distant metastases was 31.1% at diagnosis and 63.9% of the patients were operated. The median follow-up period was 27 months. The rate of three-years overall survival (OS) was 88.5% and the ve-years OS rate was 86.9%. The variables that can signi cantly in uence the OS rate were high grade (grade 3; p= 0.005), Ki-67 proliferation index (Ki-67 >20%; p= 0.002) and distant metastases (p= 0.018). Conclusion: GEP-NENs may develop anywhere in the digestive tract. Approximately one-third of the patients may be metastatic due to delay in diagnosis.
Publication Details
Page(s) 863-867
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 30, Issue: 8, Year: 2020

Request the full text from PASTIC

Keywords
Gastroenteropancreatic neuroendocrine tumor, Neuroendocrine cancers, Neuroendocrine neoplasms
0

Citations

0

Downloads

66

Views